Trials that have a more heterogeneous study population are more generalisable to clinical practice and potentially have more external validity. However, because of a number of societal and historical factors, it is a challenge for trials to achieve this desired heterogeneous population.
Find out how leading experts from the clinical trial space are combating these challenges by listening to this webinar!
In this second of two parts on the developing participant diversity movement, sponsor, CRO and site representatives discuss the impact of the FDA's recent draft guidance and the efforts they already are making to increase inclusivity in their trials.
Improving diversity in clinical trials is essential in order to produce generalizable results. Although the importance of representation has become increasingly recognized, identifying strategies to approach this work remains elusive. This article reviews the proceedings of a multi-stakeholder conference about the current state of diversity in clinical trials and outlines actionable steps for improvement.
If the clinical trial industry is serious about promoting diversity, it's time to take a holistic approach to patient outreach and eschew its current "transactional" nature, says Chris Komelasky, CEO of SiteBridge Research.
With impact investing on the rise, many of the nation's top healthcare foundations are ramping up their ground game in the Triangle. Tapping everything from talent to solutions, they say they're working to tackle growing health disparities across the country, while generating profits at the same time.
ACRP talked to Chris Komelasky, CEO & Founder of Site Bridge Research, about what steps need to be taken to broaden clinical research into underserved and minority populations.
At the AMA's November 2021 Meeting of the House of Delegates, AMA CEO James L. Madara, MD, speaks to the trust physicians place in the AMA, the trust patients place in the care, experience and expertise provided by physicians, especially during a crisis; and AMA's work in advocacy, equity and innovation.
Dr. Manesh Patel, the Richard Stack distinguished professor at Duke University School of Medicine, Chief of the Cardiology Division and co-director of the Heart Center, speaks with host Dr. M. Christine Stock, Managing Director of Medical Affairs at Health2047. They discuss Dr. Patel's involvement in clinical trials for patients with cardiovascular disease and an innovative startup that plans to bring clinical trials to independent physician practices and to patients from medically underserved communities.
Health2047 Inc., the Silicon Valley-based innovation subsidiary of the American Medical Association (AMA), has spun out portfolio company SiteBridge Research, Inc., which seeks to make clinical trials more accessible by empowering a broader set of physicians and their patients to take part in research though its novel 'Trial-In-A-Box' platform. SiteBridge Research (SiteBridge) is creating a sustainable path towards enriched real-world data (RWD) and real-world evidence (RWE), resulting in more widely applicable clinical trial results. This approach will accelerate the time to market and ultimately product adoption in communities that are harder to reach and have some of the highest unmet needs.
"We're excited by SiteBridge Research's mission to democratize clinical trials by opening access and removing barriers to different parts of the clinical trial ecosystem,"
-Lawrence K. Cohen, CEO of Health2047.
Chris Komelasky and Neile Grayson speak with host Dr. M. Christine Stock, Managing Director of Medical Affairs at Health2047. Chris Komelasky is CEO of SiteBridge Research and an advisor to Health2047and Neile Grayson is a Managing Director at Health2047. They discuss the importance of clinical research, the empowering impacts research has on a physician's practice, and how to overcome patient barriers.
